CD81 down-regulation on B cells is associated with the response to interferon-alpha-based treatment for chronic hepatitis C virus infection

Antiviral Research

Volumn 75, Issue 1, 2007, Pages 43-51

  Chang, Li Ling ^a   Cheng, Pin Nan ^a   Chen, Jiann Shiuh ^b   Young, Kung Chia ^a  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

CD81; Hepatitis C virus; Interferon alpha

Indexed keywords

2 AMINOPURINE; ALPHA2B INTERFERON; BETA INTERFERON; BETA1A INTERFERON; CD81 ANTIGEN; PROTEIN KINASE R; RIBAVIRIN;

ADULT; AGED; ARTICLE; B LYMPHOCYTE; CELL SUBPOPULATION; CLINICAL ARTICLE; CONTROLLED STUDY; DAUDI CELL; DOWN REGULATION; FEMALE; HEPATITIS C; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; LYMPHOCYTE COUNT; MALE; NATURAL KILLER CELL; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE;

ADULT; ANTIGENS, CD; ANTIVIRAL AGENTS; B-LYMPHOCYTES; CASE-CONTROL STUDIES; CELL LINE, TUMOR; CELLS, CULTURED; DOWN-REGULATION; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

HEPATITIS C VIRUS;

EID: 34247209534     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.antiviral.2006.11.009     Document Type: Article

References (41)

1. Asahina Y., Izumi N., Uchihara M., Noguchi O., Nishimura Y., Inoue K., Ueda K., Tsuchiya K., Hamano K., Itakura J., and Miyake S. Interferon-stimulated gene expression and hepatitis C viral dynamics during different interferon regimens. J. Hepatol. 39 (2003) 421-427
2. Cocquerel L., Kuo C.C., Dubuisson J., and Levy S. CD81-dependent binding of hepatitis C virus E1E2 heterodimers. J. Virol. 77 (2003) 10677-10683
3. Cramp M.E., Rossol S., Chokshi S., Carucci P., Williams R., and Naoumov N.V. Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C. Gastroenterology 118 (2000) 346-355
4. Crotta S., Stilla A., Wack A., D'Andrea A., Nuti S., D'Oro U., Mosca M., Filliponi F., Brunetto R.M., Bonino F., Abrignani S., and Valiante N.M. Inhibition of natural killer cells through engagement of CD81 by the major hepatitis C virus envelope protein. J. Exp. Med. 195 (2002) 35-41
5. Curry M.P., Golden-Mason L., Doherty D.G., Deignan T., Norris S., Duffy M., Nolan N., Hall W., Hegarty J.E., and O'Farrelly C. Expansion of innate CD5pos B cells expressing high levels of CD81 in hepatitis C virus infected liver. J. Hepatol. 38 (2003) 642-650
6. Davis G.L., Esteban-Mur R., Rustgi V., Hoefs J., Gordon S.C., Trepo C., Shiffman M.L., Zeuzem S., Craxi A., Ling M.H., and Albrecht J. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N. Engl. J. Med. 339 (1998) 1493-1499
7. Deng J., Dekruyff R.H., Freeman G.J., Umetsu D.T., and Levy S. Critical role of CD81 in cognate T-B cell interactions leading to Th2 responses. Int. Immunol. 14 (2002) 513-523
8. Flint M., Maidens C., Loomis-Price L.D., Shotton C., Dubuisson J., Monk P., Higginbottom A., Levy S., and McKeating J.A. Characterization of hepatitis C virus E2 glycoprotein interaction with a putative cellular receptor, CD81. J. Virol. 73 (1999) 6235-6244
9. Frese M., Schwarzle V., Barth K., Krieger N., Lohmann V., Mihm S., Haller O., and Bartenschlager R. Interferon-gamma inhibits replication of subgenomic and genomic hepatitis C virus RNAs. Hepatology 35 (2002) 694-703
10. Fried M.W., Shiffman M.L., Reddy K.R., Smith C., Marinos G., Goncales Jr. F.L., Haussinger D., Diago M., Carosi G., Dhumeaux D., Craxi A., Lin A., Hoffman J., and Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 347 (2002) 975-982
11. Gale Jr. M.J., Korth M.J., Tang N.M., Tan S.L., Hopkins D.A., Dever T.E., Polyak S.J., Gretch D.R., and Katze M.G. Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein. Virology 230 (1997) 217-227
12. Hellier S., Frodsham A.J., Hennig B.J., Klenerman P., Knapp S., Ramaley P., Satsangi J., Wright M., Zhang L., Thomas H.C., Thursz M., and Hill A.V. Association of genetic variants of the chemokine receptor CCR5 and its ligands, RANTES and MCP-2, with outcome of HCV infection. Hepatology 38 (2003) 1468-1476
13. Kamal S.M., Fehr J., Roesler B., Peters T., and Rasenack J.W. Peginterferon alone or with ribavirin enhances HCV-specific CD4 T-helper 1 responses in patients with chronic hepatitis C. Gastroenterology 123 (2002) 1070-1083
14. Konishi I., Horiike N., Hiasa Y., Michitaka K., and Onji M. CCR5 promoter polymorphism influences the interferon response of patients with chronic hepatitis C in Japan. Intervirology 47 (2004) 114-120
15. Kronenberger B., Ruster B., Elez R., Weber S., Piiper A., Lee J.H., Roth W.K., and Zeuzem S. Interferon alfa down-regulates CD81 in patients with chronic hepatitis C. Hepatology 33 (2001) 1518-1526
16. Kronenberger B., Herrmann E., Hofmann W.P., Wedemeyer H., Sester M., Mihm U., Ghaliai T., Zeuzem S., and Sarrazin C. Dynamics of CD81 expression on lymphocyte subsets during interferon-alpha-based antiviral treatment of patients with chronic hepatitis C. J. Leukoc. Biol. 80 (2006) 298-308
17. Lam N.P., Neumann A.U., Gretch D.R., Wiley T.E., Perelson A.S., and Layden T.J. Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa. Hepatology 26 (1997) 226-231
18. Lau J.Y., Tam R.C., Liang T.J., and Hong Z. Mechanism of action of ribavirin in the combination treatment of chronic HCV infection. Hepatology 35 (2002) 1002-1009
19. Layden J.E., Layden T.J., Reddy K.R., Levy-Drummer R.S., Poulakos J., and Neumann A.U. First phase viral kinetic parameters as predictors of treatment response and their influence on the second phase viral decline. J. Viral. Hepat. 9 (2002) 340-345
20. Lohr H.F., Schmitz D., Arenz M., Weyer S., Gerken G., and Meyer zum Buschenfelde K.H. The viral clearance in interferon-treated chronic hepatitis C is associated with increased cytotoxic T cell frequencies. J. Hepatol. 31 (1999) 407-415
21. MacQuillan G.C., de Boer W.B., Platten M.A., McCaul K.A., Reed W.D., Jeffrey G.P., and Allan J.E. Intrahepatic MxA and PKR protein expression in chronic hepatitis C virus infection. J. Med. Virol. 68 (2002) 197-205
22. Maecker H.T., Do M.S., and Levy S. CD81 on B cells promotes interleukin 4 secretion and antibody production during T helper type 2 immune responses. Proc. Natl. Acad. Sci. U.S.A. 95 (1998) 2458-2462
23. Maecker H.T. Human CD81 directly enhances Th1 and Th2 cell activation, but preferentially induces proliferation of Th2 cells upon long-term stimulation. BMC Immunol. 4 (2003) 1
24. Manns M.P., McHutchison J.G., Gordon S.C., Rustgi V.K., Shiffman M., Reindollar R., Goodman Z.D., Koury K., Ling M., and Albrecht J.K. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358 (2001) 958-965
25. McHutchison J.G., Gordon S.C., Schiff E.R., Shiffman M.L., Lee W.M., Rustgi V.K., Goodman Z.D., Ling M.H., Cort S., and Albrecht J.K. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N. Engl. J. Med. 339 (1998) 1485-1492
26. Mittelbrunn M., Yanez-Mo M., Sancho D., Ursa A., and Sanchez-Madrid F. Cutting edge: dynamic redistribution of tetraspanin CD81 at the central zone of the immune synapse in both T lymphocytes and APC. J. Immunol. 169 (2002) 6691-6695
27. Nelson D.R., Marousis C.G., Ohno T., Davis G.L., and Lau J.Y. Intrahepatic hepatitis C virus-specific cytotoxic T lymphocyte activity and response to interferon alfa therapy in chronic hepatitis C. Hepatology 28 (1998) 225-230
28. Neumann A.U., Lam N.P., Dahari H., Gretch D.R., Wiley T.E., Layden T.J., and Perelson A.S. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 282 (1998) 103-107
29. Pawlotsky J.M. Mechanisms of antiviral treatment efficacy and failure in chronic hepatitis C. Antiviral Res. 59 (2003) 1-11
30. Pileri P., Uematsu Y., Campagnoli S., Galli G., Falugi F., Petracca R., Weiner A.J., Houghton M., Rosa D., Grandi G., and Abrignani S. Binding of hepatitis C virus to CD81. Science 282 (1998) 938-941
31. Poynard T., McHutchison J., Davis G.L., Esteban-Mur R., Goodman Z., Bedossa P., and Albrecht J. Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C. Hepatology 32 (2000) 1131-1137
32. Promrat K., McDermott D.H., Gonzalez C.M., Kleiner D.E., Koziol D.E., Lessie M., Merrell M., Soza A., Heller T., Ghany M., Park Y., Alter H.J., Hoofnagle J.H., Murphy P.M., and Liang T.J. Associations of chemokine system polymorphisms with clinical outcomes and treatment responses of chronic hepatitis C. Gastroenterology 124 (2003) 352-360
33. Schroter M., Zollner B., Schafer P., Landt O., Lass U., Laufs R., and Feucht H.H. Genotyping of hepatitis C virus types 1, 2, 3, and 4 by a one-step LightCycler method using three different pairs of hybridization probes. J. Clin. Microbiol. 40 (2002) 2046-2050
34. Secrist H., Levy S., DeKruyff R.H., and Umetsu D.T. Ligation of TAPA-1 (CD81) or major histocompatibility complex class II in co-cultures of human B and T lymphocytes enhances interleukin-4 synthesis by antigen-specific CD4+ T cells. Eur. J. Immunol. 26 (1996) 1435-1442
35. Suzuki F., Arase Y., Suzuki Y., Tsubota A., Akuta N., Hosaka T., Someya T., Kobayashi M., Saitoh S., Ikeda K., Kobayashi M., Matsuda M., Takagi K., Satoh J., and Kumada H. Single nucleotide polymorphism of the MxA gene promoter influences the response to interferon monotherapy in patients with hepatitis C viral infection. J. Viral. Hepat. 11 (2004) 271-276
36. Taylor D.R., Shi S.T., Romano P.R., Barber G.N., and Lai M.M. Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein. Science 285 (1999) 107-110
37. Tsai S.L., Sheen I.S., Chien R.N., Chu C.M., Huang H.C., Chuang Y.L., Lee T.H., Liao S.K., Lin C.L., Kuo G.C., and Liaw Y.F. Activation of Th1 immunity is a common immune mechanism for the successful treatment of hepatitis B and C: tetramer assay and therapeutic implications. J. Biomed. Sci. 10 (2003) 120-135
38. Tseng C.T., and Klimpel G.R. Binding of the hepatitis C virus envelope protein E2 to CD81 inhibits natural killer cell functions. J. Exp. Med. 195 (2002) 43-49
39. Wack A., Soldaini E., Tseng C., Nuti S., Klimpel G., and Abrignani S. Binding of the hepatitis C virus envelope protein E2 to CD81 provides a co-stimulatory signal for human T cells. Eur. J. Immunol. 31 (2001) 166-175
40. Zuckerman E., Slobodin G., Kessel A., Sabo E., Yeshurun D., Halas K., and Toubi E. Peripheral B-cell CD5 expansion and CD81 overexpression and their association with disease severity and autoimmune markers in chronic hepatitis C virus infection. Clin. Exp. Immunol. 128 (2002) 353-358
41. Zuckerman E., Kessel A., Slobodin G., Sabo E., Yeshurun D., and Toubi E. Antiviral treatment down-regulates peripheral B-cell CD81 expression and CD5 expansion in chronic hepatitis C virus infection. J. Virol. 77 (2003) 10432-10436